Affimed

Affimed Gross Margin

Delisted

The Gross Margin of Affimed (AFMD) as of Nov 19, 2026 is 100.00 %. In the previous year, Gross Margin was 100.00 % — a change of 0.00% (lower).

Gross Margin

100.00 %

YoY

0.00%

Last updated:

Gross Margin of Affimed is 2023 100.00 % . Gross Margin of Affimed was 2022 100.00 % . It decreases by 0.00% lower compared to the previous year.

Affimed's gross margin stands at 100.0%, broadly stable from 100.0% several years earlier.

The Affimed Gross Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Margin
Date
Gross Margin
Jan 1, 2016
100.00 EUR
Jan 1, 2017
100.00 EUR
Jan 1, 2018
100.00 EUR
Jan 1, 2019
100.00 EUR
Jan 1, 2020
100.00 EUR
Jan 1, 2021
100.00 EUR
Jan 1, 2022
100.00 EUR
Jan 1, 2023
100.00 EUR
The Affimed Gross Margin history
YEARGross MarginYoY
100.00 %0.00%
100.00 %0.00%
100.00 %0.00%
100.00 %0.00%
100.00 %0.00%
100.00 %0.00%
100.00 %0.00%
100.00 %0.00%
100.00 %0.00%
100.00 %+9,900.00%
1.00 %0.00%
1.00 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Affimed Stock analysis

What does Affimed do? Affimed NV develops targeted cancer immunotherapies focused on immuno-oncology, leveraging the immune system to combat tumor cells. The company's product pipeline includes AFM13 for CD30-positive relapsed/refractory peripheral T-cell Lymphoma, AFM13 combined with adoptive NK cells or anti-PD-1, and AFM24 for advanced EGFR-expressing solid tumors. Affimed is conducting a registration-directed study for AFM13 and a Phase 1/2a study for AFM24, alongside preclinical candidates like AMF26 for multiple myeloma and AMF28/AMF32 for multiple tumor targets. The firm collaborates with Genentech to develop and commercialize certain product candidates for multiple cancers. Affimed generates revenue primarily through collaboration agreements, such as the partnership with Genentech, which covers development and commercialization of specific therapies. The company's primary customers are pharmaceutical and biotechnology firms seeking to expand their oncology portfolios, particularly those interested in immuno-oncology approaches. Affimed's target segments include patients with relapsed/refractory peripheral T-cell Lymphoma, advanced EGFR-expressing solid tumors, and multiple myeloma, as well as broader oncology markets for its preclinical candidates. The company's revenue streams are tied to milestone payments and potential royalties from partnered products, with Genentech being a key collaborator. Affimed's focus on immuno-oncology positions it to attract partnerships with major pharmaceutical players looking to enhance their cancer therapy offerings. Its clinical-stage products, such as AFM13 and AFM24, are in advanced development phases, making them attractive for strategic alliances that drive commercialization and revenue generation. Affimed is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Affimed stock

Gross Margin of Affimed is 100.00 % in 2023.

Gross Margin of Affimed changed from 100.00 % to 100.00 %, representing a 0.00% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin Affimed since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's Affimed with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Affimed

All Key Metrics — Affimed